Trial intelligence / Profile preview

First-in-human multiple ascending dose trial of intrathecal S233107 in spinocerebellar ataxia type 3

2025-525111-17-00Phase 2Completed

Sponsor: Servier
Start: Jul 2026
Countries: 6

Overview

Phase 2, randomised, double-blind trial of S233107 in machado-joseph disease (MJD) (3 arms), sponsored by Servier. Started Jul 2026; status: completed.

Drugs

S233107

Conditions

machado-joseph disease (MJD)

Beyond the preview

Go deeper on 2025-525111-17-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-525111-17-00.